Editas Medicine, Inc.
EDIT
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIā¦ read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.65
Price+2.71%
$0.07
1Y
Price
Market Cap
$259.436m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-827.5%
EBITDA Margin-882.4%
Net Profit Margin-817.8%
Free Cash Flow Margin-827.5%
EBITDA Margin-882.4%
Net Profit Margin-817.8%
Free Cash Flow MarginRevenue
$38.693m
-4.5%
1y CAGR-12.6%
3y CAGR+64.6%
5y CAGREarnings
-$108.954m
+31.9%
1y CAGR+3.2%
3y CAGR+10.0%
5y CAGREPS
-$1.23
+31.7%
1y CAGR+8.9%
3y CAGR+15.9%
5y CAGRBook Value
$4.408m
$149.338m
Assets$144.930m
Liabilities$71.974m
DebtDebt to Assets
48.2%
-0.7x
Debt to EBITDAFree Cash Flow
-$141.088m
+14.9%
1y CAGR-6.9%
3y CAGR+0.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company